PE20230830A1 - Formulaciones farmaceuticas de acetato de abiraterona y niraparib - Google Patents
Formulaciones farmaceuticas de acetato de abiraterona y niraparibInfo
- Publication number
- PE20230830A1 PE20230830A1 PE2022002554A PE2022002554A PE20230830A1 PE 20230830 A1 PE20230830 A1 PE 20230830A1 PE 2022002554 A PE2022002554 A PE 2022002554A PE 2022002554 A PE2022002554 A PE 2022002554A PE 20230830 A1 PE20230830 A1 PE 20230830A1
- Authority
- PE
- Peru
- Prior art keywords
- abiraterone acetate
- niraparib
- pharmaceutical formulations
- composition
- glidant
- Prior art date
Links
- 229960004103 abiraterone acetate Drugs 0.000 title abstract 2
- UVIQSJCZCSLXRZ-UBUQANBQSA-N abiraterone acetate Chemical compound C([C@@H]1[C@]2(C)CC[C@@H]3[C@@]4(C)CC[C@@H](CC4=CC[C@H]31)OC(=O)C)C=C2C1=CC=CN=C1 UVIQSJCZCSLXRZ-UBUQANBQSA-N 0.000 title abstract 2
- 229950011068 niraparib Drugs 0.000 title abstract 2
- PCHKPVIQAHNQLW-CQSZACIVSA-N niraparib Chemical compound N1=C2C(C(=O)N)=CC=CC2=CN1C(C=C1)=CC=C1[C@@H]1CCCNC1 PCHKPVIQAHNQLW-CQSZACIVSA-N 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 102000001307 androgen receptors Human genes 0.000 abstract 2
- 108010080146 androgen receptors Proteins 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000007884 disintegrant Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000008187 granular material Substances 0.000 abstract 1
- 239000008202 granule composition Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 239000000080 wetting agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Epoxy Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20173749 | 2020-05-08 | ||
| US202163142919P | 2021-01-28 | 2021-01-28 | |
| US202163174282P | 2021-04-13 | 2021-04-13 | |
| PCT/EP2021/062188 WO2021224471A1 (en) | 2020-05-08 | 2021-05-07 | Pharmaceutical formulations of abiraterone acetate and niraparib |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20230830A1 true PE20230830A1 (es) | 2023-05-19 |
Family
ID=75888052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2022002554A PE20230830A1 (es) | 2020-05-08 | 2021-05-07 | Formulaciones farmaceuticas de acetato de abiraterona y niraparib |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US20230226080A1 (https=) |
| EP (3) | EP4146210A1 (https=) |
| JP (3) | JP2023524808A (https=) |
| KR (3) | KR20230008780A (https=) |
| CN (3) | CN115515584A (https=) |
| AU (5) | AU2021267146B2 (https=) |
| BR (3) | BR112022021732A2 (https=) |
| CA (3) | CA3177123A1 (https=) |
| CR (1) | CR20220588A (https=) |
| EC (1) | ECSP22085983A (https=) |
| IL (3) | IL297984B2 (https=) |
| JO (3) | JOP20220294A1 (https=) |
| MX (3) | MX2022014003A (https=) |
| PE (1) | PE20230830A1 (https=) |
| PH (3) | PH12022553029A1 (https=) |
| TW (3) | TWI905184B (https=) |
| UA (1) | UA130040C2 (https=) |
| UY (3) | UY39204A (https=) |
| WO (3) | WO2021224467A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243120A1 (en) * | 2022-02-04 | 2023-08-10 | Janssen Pharmaceutica Nv | Niraparib and abiraterone acetate plus prednisone to improve clinical outcomes in patients with metastatic castration-resistant prostate cancer and changes in hormone receptor function (HRF) |
| WO2025027138A1 (en) * | 2023-08-02 | 2025-02-06 | Janssen Pharmaceutica Nv | Combination of niraparib and abiraterone for use in the treatment of metastatic castration-resistant prostate cancer |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2132449C (en) | 1992-03-31 | 2002-09-10 | Susan E. Barrie | 17 - substituted steroids useful in cancer treatment |
| JP2003104888A (ja) * | 2001-09-28 | 2003-04-09 | Taiyo Yakuhin Kogyo Kk | ジヒドロピリジン誘導体の錠剤 |
| BRPI0719236A2 (pt) * | 2006-10-13 | 2014-07-08 | Janssen Pharmaceutica Nv | Composições de carbamato de fenilalquila |
| JP4611444B2 (ja) | 2007-01-10 | 2011-01-12 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ポリ（ａｄｐ−リボース）ポリメラーゼ（ｐａｒｐ）阻害剤としてのアミド置換インダゾール |
| KR101653548B1 (ko) | 2008-01-08 | 2016-09-02 | 머크 샤프 앤드 돔 리미티드 | 2-｛4-［（3ｓ）-피페리딘-3-일］페닐｝-2ｈ-인다졸-7-카복스아미드의 약제학적으로 허용되는 염 |
| CN102026628A (zh) * | 2008-02-15 | 2011-04-20 | 太阳医药高级研发有限公司 | 具有降低崩裂效果的口服控释片剂 |
| CA2808501A1 (en) * | 2010-08-23 | 2012-03-01 | Vertex Pharmaceuticals Incorporated | Pharmaceutical composition of (r)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-n-(1-(2,3-dihydroxy propyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1h-indol-5-yl) cyclopropanecarboxamide and administration therof |
| CN102743393A (zh) * | 2012-07-27 | 2012-10-24 | 海南盛科生命科学研究院 | 一种含有醋酸阿比特龙的药物组合物及制备工艺 |
| HK1213197A1 (zh) * | 2013-03-04 | 2016-06-30 | Vtv治疗有限责任公司 | 包括葡糖激酶活化劑的固體組合物及其製備和使用方法 |
| WO2015032873A1 (en) * | 2013-09-06 | 2015-03-12 | Synthon B.V. | High-load pharmaceutical compositions comprising abiraterone acetate |
| EP3160450A1 (en) * | 2014-06-30 | 2017-05-03 | Galenicum Health S.L. | Stable pharmaceutical compositions in the form of immediate release tablets |
| SG11201701139YA (en) * | 2014-09-18 | 2017-03-30 | Iceutica Inc | Abiraterone acetate formulation and methods of use |
| SG11201811564QA (en) * | 2016-06-29 | 2019-01-30 | Tesaro Inc | Methods of treating ovarian cancer |
| CN110944638A (zh) * | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| HUE060460T2 (hu) * | 2017-04-13 | 2023-03-28 | Janssen Pharmaceutica Nv | Niraparib, abirateron-acetát és prednizon prosztatarák kezelésére |
| TWI843707B (zh) * | 2017-09-26 | 2024-06-01 | 美商提薩羅有限公司 | 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物 |
| JOP20200072A1 (ar) * | 2017-10-11 | 2020-04-29 | Janssen Oncology Inc | طرق علاج سرطان البروستاتا من خلال إعطاء أسيتات الأبيراتيرون إلى جانب البريدنيزون مع المعالجة بحرمان الأندروجين |
| CA3098208A1 (en) * | 2018-04-26 | 2019-10-31 | Synthon B.V. | Tablet compositions comprising abiraterone acetate |
| CN113166071B (zh) | 2018-10-03 | 2025-03-21 | 特沙诺有限公司 | 尼拉帕利盐 |
-
2021
- 2021-05-07 TW TW110116507A patent/TWI905184B/zh active
- 2021-05-07 KR KR1020227042483A patent/KR20230008780A/ko active Pending
- 2021-05-07 UY UY0001039204A patent/UY39204A/es unknown
- 2021-05-07 BR BR112022021732A patent/BR112022021732A2/pt unknown
- 2021-05-07 TW TW110116509A patent/TWI894266B/zh active
- 2021-05-07 IL IL297984A patent/IL297984B2/en unknown
- 2021-05-07 PH PH1/2022/553029A patent/PH12022553029A1/en unknown
- 2021-05-07 MX MX2022014003A patent/MX2022014003A/es unknown
- 2021-05-07 JP JP2022567542A patent/JP2023524808A/ja active Pending
- 2021-05-07 WO PCT/EP2021/062180 patent/WO2021224467A1/en not_active Ceased
- 2021-05-07 WO PCT/EP2021/062186 patent/WO2021224469A1/en not_active Ceased
- 2021-05-07 US US17/998,202 patent/US20230226080A1/en active Pending
- 2021-05-07 EP EP21725098.4A patent/EP4146210A1/en active Pending
- 2021-05-07 AU AU2021267146A patent/AU2021267146B2/en active Active
- 2021-05-07 BR BR112022022590A patent/BR112022022590A2/pt active IP Right Grant
- 2021-05-07 CN CN202180033488.6A patent/CN115515584A/zh active Pending
- 2021-05-07 UY UY0001039201A patent/UY39201A/es unknown
- 2021-05-07 IL IL297991A patent/IL297991A/en unknown
- 2021-05-07 US US17/998,198 patent/US20230218640A1/en active Pending
- 2021-05-07 CA CA3177123A patent/CA3177123A1/en active Pending
- 2021-05-07 AU AU2021269115A patent/AU2021269115A1/en active Pending
- 2021-05-07 CA CA3177137A patent/CA3177137A1/en active Pending
- 2021-05-07 CN CN202180033482.9A patent/CN115515583A/zh active Pending
- 2021-05-07 JP JP2022567447A patent/JP2023525026A/ja active Pending
- 2021-05-07 UY UY0001039203A patent/UY39203A/es unknown
- 2021-05-07 JP JP2022567451A patent/JP2023524794A/ja active Pending
- 2021-05-07 PH PH1/2022/553013A patent/PH12022553013A1/en unknown
- 2021-05-07 EP EP21725101.6A patent/EP4146211A1/en active Pending
- 2021-05-07 UA UAA202204571A patent/UA130040C2/uk unknown
- 2021-05-07 EP EP21724665.1A patent/EP4146209A1/en active Pending
- 2021-05-07 PE PE2022002554A patent/PE20230830A1/es unknown
- 2021-05-07 MX MX2022014005A patent/MX2022014005A/es unknown
- 2021-05-07 IL IL297990A patent/IL297990A/en unknown
- 2021-05-07 PH PH1/2022/553030A patent/PH12022553030A1/en unknown
- 2021-05-07 CN CN202180033483.3A patent/CN115551506A/zh active Pending
- 2021-05-07 KR KR1020227042489A patent/KR20230008782A/ko active Pending
- 2021-05-07 MX MX2022014004A patent/MX2022014004A/es unknown
- 2021-05-07 CA CA3177094A patent/CA3177094A1/en active Pending
- 2021-05-07 WO PCT/EP2021/062188 patent/WO2021224471A1/en not_active Ceased
- 2021-05-07 BR BR112022022534A patent/BR112022022534A2/pt active IP Right Grant
- 2021-05-07 TW TW110116506A patent/TW202207925A/zh unknown
- 2021-05-07 AU AU2021266409A patent/AU2021266409A1/en active Pending
- 2021-05-07 KR KR1020227042495A patent/KR20230008783A/ko active Pending
- 2021-05-07 US US17/998,204 patent/US20230226081A1/en active Pending
- 2021-05-07 CR CR20220588A patent/CR20220588A/es unknown
-
2022
- 2022-11-01 JO JOJO/P/2022/0294A patent/JOP20220294A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0288A patent/JOP20220288A1/ar unknown
- 2022-11-01 JO JOJO/P/2022/0292A patent/JOP20220292A1/ar unknown
- 2022-11-08 EC ECSENADI202285983A patent/ECSP22085983A/es unknown
-
2025
- 2025-12-11 US US19/415,909 patent/US20260097048A1/en active Pending
-
2026
- 2026-03-23 AU AU2026202227A patent/AU2026202227A1/en active Pending
- 2026-03-25 AU AU2026202283A patent/AU2026202283A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6797980B2 (ja) | ルカパリブの高投与力価錠剤 | |
| KR102464646B1 (ko) | (r)-2-아미노-3-페닐프로필 카바메이트의 제제 | |
| CN103550165B (zh) | 一种含有利伐沙班的药物组合物及其制备方法 | |
| NZ734446A (en) | Pharmaceutical formulations of bruton’s tyrosine kinase inhibtor | |
| CN105250231B (zh) | 一种含有依托考昔的药物组合物及其制备方法 | |
| NZ599430A (en) | A drug delivery system for the prevention of cerebral vasospasm | |
| PE20230830A1 (es) | Formulaciones farmaceuticas de acetato de abiraterona y niraparib | |
| CN107080742A (zh) | 经口施用的固体剂型药物组合物 | |
| CN104434931A (zh) | 含替格瑞洛和阿司匹林的复方口服固体剂及其制备方法 | |
| JPH05194238A (ja) | Ｗｉｎ４９５９６−フィナステリドの使用方法及び組成物 | |
| EP3150201A1 (en) | Composite preparation comprising 5- -reductase inhibitor-containing film coating layer, and method for producing the composite preparation | |
| KR20050044468A (ko) | 비칼루타미드를 포함하는 약학 제제 | |
| CN108201535A (zh) | 一种维利帕尼缓控释药物组合物及其用途 | |
| CN109125270B (zh) | 一种固体制剂及其制备方法 | |
| CN104800184A (zh) | 琥珀酸呋罗曲坦缓释剂片 | |
| Wang et al. | Enhancing the solubility and dose delivery of drospirenone through oxidized regenerated cellulose hydrogel compound with liposome system | |
| JP2019147798A (ja) | ダサチニブ無水物の結晶形態が安定に維持された固形製剤の製造方法 | |
| CN101703510A (zh) | 一种坦洛新和非那雄胺复方缓释片及其制备方法 | |
| TWI829840B (zh) | 醫藥組成物 | |
| CN102198113A (zh) | 一种富马酸喹硫平缓释片制备工艺 | |
| CN102423482B (zh) | 复方氨氯地平赖诺普利片的制备方法 | |
| CN106880598A (zh) | 一种依折麦布片剂 | |
| CN104739790B (zh) | 一种治疗前列腺增生的非那雄胺片剂及其制备方法 | |
| JP2020176090A (ja) | ダサチニブ無水物を含有する固形製剤の製造方法 | |
| US20250255822A1 (en) | Triptolide formulations |